Overview
Very actively managed equity fund. The portfolio is primarily focused on securities from large companies though strategically supplemented by securities from small and medium-sized companies.
The fund manager is given great flexibility to take focused views on the most attractive stocks and exploit the best opportunities, unconstrained by the reference index.
The fund offers investors a broader diversification compared to the index including lower maximum single stock weights (max. 10%) and a more balanced sector allocation.
The portfolio manager is not tied to the benchmark in terms of investment selection or weight.
The exchange rate risk between CHF and EUR is not hedged.
Benefits
The fund draws on the knowledge of proven investment specialists based in Zurich (Switzerland).
Due to the significant deviation from the reference index, the fund offers the potential to outperform the reference index.
UBS's proprietary fundamental valuation approach allows consistent selection of attractive Swiss companies.
Investors benefit from a global investment platform of UBS SA国际传谋.
Risks
Features
| Product category |
UBS Equity Funds UBS Opportunity Equity Funds |
| Product domicile |
Luxembourg
|
| Portfolio management |
UBS SA国际传谋 Switzerland AG, Zurich
|
| Fund management |
UBS SA国际传谋 (Europe) S.A., Luxembourg
|
| Custodian bank |
UBS Europe SE, Luxembourg Branch
|
| Representative for products established under foreign law |
BNP PARIBAS Securities Services
|
| Day of inception |
November 16, 2010
|
| Currency of account |
CHF
|
| Currency of unit class |
EUR
|
| Close of financial year |
May 31
|
| SFDR Classification |
Art.8
|
| Issue / redemption |
daily
|
| Distribution |
Reinvestment
|
| Maturity |
Open end
|
| Ongoing costs p.a. |
1.58% p.a.
|
| Management fee |
1.20% p.a.
|
| Total expense ratio (TER) |
1.57% p.a.
|
| Swing pricing |
yes
|
| Minimum investment |
n.a.
|
| Reference Index / Benchmark |
SPI® (TR)
|
| ISIN |
LU0546268359
|
| Bloomberg Ticker |
UBSSOPE LX
|
| Telekurs Id |
n.a.
|
Performance and Prices
Percentage growth
as of April 23, 2026| EUR(%) | |
| YTD | 3.08 |
| 1M | |
| 3M | |
| 6M | |
| 1Y | 17.86 |
| 2Y | 29.40 |
| 3Y | 27.45 |
| 5Y | 43.62 |
| ø p.a.5Y |
Current data
| Net asset value | 23.04.2026 | EUR 383.19 |
| High - last 12 months | 27.02.2026 | EUR 401.17 |
| Low - last 12 months | 24.04.2025 | EUR 327.72 |
| Assets of the unit class in mn | 23.04.2026 | EUR 10.73 |
| Total product assets in mn | 23.04.2026 | EUR 73.15 |
|
Date
|
2 years
|
5 years
|
|
| Total risk reference index / benchmark | 31.03.2026 | 13.14% | 13.18% |
| Sharpe Ratio | 31.03.2026 | 0.52 | 0.38 |
| Risk Free Rate | 31.03.2026 | 2.75% | 1.89% |
Structures
By the 10 largest equity positions (in %, as of March 31, 2026)
|
|
|
| Nestle SA | 9.90 |
| Novartis AG | 9.85 |
| Roche Holding AG | 9.39 |
| Zurich Insurance Group AG | 8.04 |
| UBS Group AG | 5.08 |
| Swiss Re AG | 5.04 |
| ABB Ltd | 4.72 |
| Cie Financiere Richemont SA | 4.26 |
| Givaudan SA | 3.90 |
| Lonza Group AG | 3.53 |
Fees
Distributions
Sales Authorisations
Literature
|
Document type
|
Document Language
|
|
| Prospectus |
|
|
| Key Information Document |
|
|
| Past performance |
|
|
| Previous performance scenario |
|
|
|
Document type
|
Document Language
|
|
| Annual report |
|
|
| Semi-annual report |
|
|